Ester prodrug of scutellarin: Synthesis, physicochemical property and degradation

Yaoxue Xuebao

Volumn 41, Issue 7, 2006, Pages 595-602

  Cao, Feng ^a   Guo, Jian Xin ^a   Ping, Qi Neng ^a   Shao, Yun ^a   Liang, Jing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cyclodextrin complex; Emulsion; Glycolamide ester; Intestinal degradation; Physicochemical property; Prodrug; Scutellarin; Synthesis

Indexed keywords

APIGENIN; BENZYL SCUTELLARIN; ESTER; ETHYL SCUTELLARIN; FLAVONE DERIVATIVE; GLUCURONIC ACID; GLUCURONIDE; N,N DIETHYLGLYCOLAMIDE 4',5,6 TRIHYDROXYFLAVONE 7 GLUCURONIDE ESTER; N,N-DIETHYLGLYCOLAMIDE-4',5,6-TRIHYDROXYFLAVONE-7-GLUCURONIDE ESTER; PRODRUG; SCUTELLARIN;

ANIMAL; ARTICLE; CHEMISTRY; EMULSION; ERIGERON; HUMAN; INTESTINE; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MALE; MEDICINAL PLANT; METABOLISM; RAT; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; APIGENIN; EMULSIONS; ERIGERON; ESTERS; FLAVONES; GLUCURONIC ACIDS; GLUCURONIDES; HUMANS; INTESTINAL MUCOSA; INTESTINES; MALE; PLANTS, MEDICINAL; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33748944180     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Liu H, Yang XL, Wang Y, et al. Protective effects of scutellarin on superoxide-induced oxidative stress in rat cortical synaptosomes [J]. Acta Pharmacol Sin, 2003, 24:1113-1117.
2. Chen XX, He B. Effects of breviscapine on the changes in antioxidant enzyme activity induced by cerebral ischemia reperfusion in rats [J]. J Chin Pharm Sci, 1998, 7:91-93.
3. Xu QY, Li XX. Influence of DZXX injection on blood viscosity in patients with high blood viscosity [J]. New Drugs Clin Rem, 1995, 14:233.
4. Ge QH, Zhou Z, Zhi XJ, et al. Pharmacokinetics and absolute bioavailability of breviscapine in beagle dogs [J]. Chi J Pharm, 2003, 34:618-620.
5. Zhang HY, Ping QN, Guo JX, et al. Study on the pharmacokinetics of breviscapine and its β-cyclodextrin complex in rats [J]. Acta Pharm Sin, 2005, 40:563-567.
6. Todd PA, Heel RC, Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure [J]. Drugs, 1986, 31:198-248.
7. Stimpel M, Bonn R, Koch B, et al. Pharmacology and clinical use of the new ACE-inhibitor moexipril [J]. Cardiovasc Drug Rev, 1995, 13:211-229.
8. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 [J]. Clin Pharmacokinet, 1999, 37:471-484.
9. Ginsburg CM, McCracken GH, Petruska M, et al. Pharmacokinetics and bactericidal activity of cefuroxime axetil [J]. Antimicrob Agents Chemother, 1985, 28:504-507.
10. 14C-camostat mesylate in man, rat and dog after intravenous administration [J]. Xenobiotica, 1994, 24:79-92.
11. Beaumont K, Webster R, Gardner I, et al, Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist [J]. Current Drug Metabolism, 2003, 4:461-485
12. Prueksaritanont T, Gorham LM, Hochman JH, et al. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells [J]. Drug Metab Dispos, 1996, 24:634-642.
13. Crauste-Manciet S, Brossard D, Decroix MO, et al. Cefpodoxime-proxetil protection from intestinal lumen hydrolysis by oil-in water submicron emulsions [J]. Int J Pharm, 1998, 165:97-106
14. Hirayama F, Ogata T, Yano H. Release characteristics of a short-chain fatty acid, n-butyric acid, from its β-cyclodextrin ester conjugate in rat biological media [J]. J Pharm Sci, 2000, 89:1487-1494.
15. Chan HO, Schmid HL, Stilgenbauer LA, et al. Evaluation of a targeted prodrug strategy to enhance oral absorption of prooly water-soluble compounds [J]. Pharm Res, 1998, 15:1012-1018.
16. Dias CS, Anand BS, Mitra Ak. Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs [J]. J Pharm Sci, 2001, 91:660-668.
17. Bundgaard H, Nielsen NM. Glycolamide ester as a novel biolabile prodrug type for non-steroidal anti-inflammatory carboxylic acid drugs [J]. Int J Pharm, 1988, 43:101-110.
18. Sinha VR, Anitha R, Ghosh S, et al. Complexation of celecoxib with β-cyclodextrin: characterization of the interaction in solution and in solid state [J]. J Pharm Sci, 2005, 94:676-687.
19. Nicolaos G, Crauste-Manciet S, Farinotti R, et al. Improvement of cefpodoxime proxetil oral absorption in rats by oil-in water submicron emulsion [J]. Int J Pharm, 2003, 263:165-171.
20. Yano H, Hirayama F, Kamada M, et al. Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administration [J]. J Control Release, 2002, 79:103-112.
21. Leisen C, Langguth P, Herbert B, et al. Lipophilicities of baclofen ester prodrugs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein: relevance for their permeation across the blood-brain barrier? [J]. Pharm Res, 2003, 20:772-778.
22. Nielsen NM, Bundgaard H. Glycolamide ester as biolabile prodrugs of carboxylic acid agents: synthesis, stability, bioconversion and physicochemical properties [J]. J Pharm Sci, 1988, 77:285-298.
23. Satuo T, Taylor P, Boston WF, et al. Current progress on esterases: from molecular structure to function [J]. Drug Metab Dispos, 2002, 30:488-493.
24. Mccracken NW, Blain PG, Williams FM. Human xenobiotic metabolizing esterases in liver and blood [J]. Biochem Pharmacol, 1993, 46:1125-1129.
25. Bundgaard H. Novel chemical approaches in prodrug design [J]. Drugs Fut, 1991, 16:443-458.
26. Chen J, Lin HM, Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition [J]. J Pharmcol Exp Ther, 2003, 304:1228-1235.
27. La Du BN, Snady H. Handbook of Experimental Pharmacology - Concepts in Biochemical Pharmacology [M]. 2nd ed. Berlin: Brodie BB and Gilette JR, 1971: 477-499.
28. Gelder JV, Shafiee M, Clercq ED, et al. Species-dependent and site-specific intestinal metabolism of ester prodrugs [J]. Int J Pharm, 2000, 205:93-100.
29. Cook CS, Karabatsos PJ, Schoenhard GL, et al. Species dependent esterase activities for hydrolysis of anti-HIV prodrug glycovir and bioavailability of active sc-48334 [J]. Pharm Res, 1995, 12:1158-1164.
30. Ungell AL, Bergstrand SB, Sjoberg A, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat [J]. J Pharm Sci, 1998, 87:360-366.